LZTS2 and hepatocellular carcinoma: Clinically, LZTS2 is significantly downregulated, and a low level of LZTS2 is associated with poor clinical outcomes in HCC, implying that LZTS2 may act as a tumor suppressor and serve as a potential prognostic biomarker in HCC.